Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Interest Expenses (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Interest Expenses readings, the most recent being $10.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 5.96% year-over-year to $10.8 million, compared with a TTM value of $44.3 million through Dec 2025, up 9.74%, and an annual FY2025 reading of $44.3 million, up 9.74% over the prior year.
  • Interest Expenses hit $10.8 million in Q4 2025 for Apellis Pharmaceuticals, down from $11.3 million in the prior quarter.
  • The five-year high for Interest Expenses was $12.5 million in Q3 2024, with the low at $1.2 million in Q4 2021.
  • Median Interest Expenses over the past 5 years was $7.8 million (2022), compared with a mean of $7.9 million.
  • The sharpest move saw Interest Expenses tumbled 87.51% in 2021, then soared 544.83% in 2022.
  • Year by year, Interest Expenses stood at $1.2 million in 2021, then surged by 544.83% to $7.7 million in 2022, then fell by 4.34% to $7.4 million in 2023, then skyrocketed by 55.82% to $11.5 million in 2024, then fell by 5.96% to $10.8 million in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $10.8 million, $11.3 million, and $11.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.